Interim Report, January-March 2006

-Net sales amounted to MSEK 50.3 (1.2) -Profit after tax was MSEK 15.3 (loss: 18.8) -Earnings per share amounted to SEK 1.15 (loss: 2.04) Key events during the first quarter of 2006 -Orexo received its first payment of MSEK 46.6, in January 2006, for the licensing agreement with ProStrakan Group plc relating to Rapinyl™ for the European market. Key events after the close of the period -The subsidiary Kibion AB acquired Noster System AB, with net sales of MSEK 11.4 in 2005. -Increased investment in Sublinox™ (OX 22) for treating sleep disturbances. -On April 27, Orexo held its Annual General Meeting – the Board of Directors was re-elected. For report in full format, see enclosed pdf. Financial Hearings You are welcome to follow CEO Zsolt Lavotha´s presentation of the Interim Report through webcasting, May 12 at 8.30 CET. Visit for more info. For more information, please contact: Zsolt Lavotha, CEO, Tel: +46 (0)18-780 88 12, e-mail: Claes Wenthzel, Executive Vice President and CFO, Tel: +46 (0)18-780 88 44, e-mail: